Could dexmedetomidine be repurposed as a glymphatic enhancer?

Research output: Contribution to journal › Review › Research › peer-review

Standard

Could dexmedetomidine be repurposed as a glymphatic enhancer? / Persson, Niklas Daniel Åke; Uusalo, Panu; Nedergaard, Maiken; Lohela, Terhi J.; Lilius, Tuomas O.

In: Trends in Pharmacological Sciences, Vol. 43, No. 12, 2022, p. 1030-1040.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Persson, NDÅ, Uusalo, P, Nedergaard, M, Lohela, TJ & Lilius, TO 2022, 'Could dexmedetomidine be repurposed as a glymphatic enhancer?', Trends in Pharmacological Sciences, vol. 43, no. 12, pp. 1030-1040. https://doi.org/10.1016/j.tips.2022.09.007

APA

Persson, N. D. Å., Uusalo, P., Nedergaard, M., Lohela, T. J., & Lilius, T. O. (2022). Could dexmedetomidine be repurposed as a glymphatic enhancer? Trends in Pharmacological Sciences, 43(12), 1030-1040. https://doi.org/10.1016/j.tips.2022.09.007

Vancouver

Persson NDÅ, Uusalo P, Nedergaard M, Lohela TJ, Lilius TO. Could dexmedetomidine be repurposed as a glymphatic enhancer? Trends in Pharmacological Sciences. 2022;43(12):1030-1040. https://doi.org/10.1016/j.tips.2022.09.007

Author

Persson, Niklas Daniel Åke ; Uusalo, Panu ; Nedergaard, Maiken ; Lohela, Terhi J. ; Lilius, Tuomas O. / Could dexmedetomidine be repurposed as a glymphatic enhancer?. In: Trends in Pharmacological Sciences. 2022 ; Vol. 43, No. 12. pp. 1030-1040.

Bibtex

@article{9d4d58cc583f480ea4f482d3d949aa2f,
title = "Could dexmedetomidine be repurposed as a glymphatic enhancer?",
abstract = "Cerebrospinal fluid (CSF) flows through the central nervous system (CNS) via the glymphatic pathway to clear the interstitium of metabolic waste. In preclinical studies, glymphatic fluid flow rate increases with low central noradrenergic tone and slow-wave activity during natural sleep and general anesthesia. By contrast, sleep deprivation reduces glymphatic clearance and leads to intracerebral accumulation of metabolic waste, suggesting an underlying mechanism linking sleep disturbances with neurodegenerative diseases. The selective α2-adrenergic agonist dexmedetomidine is a sedative drug that induces slow waves in the electroencephalogram, suppresses central noradrenergic tone, and preserves glymphatic outflow. As recently developed dexmedetomidine formulations enable self-administration, we suggest that dexmedetomidine could serve as a sedative-hypnotic drug to enhance clearance of harmful waste from the brain of those vulnerable to neurodegeneration.",
keywords = "cerebrospinal fluid, delirium, dexmedetomidine, glymphatic system, neurodegeneration, α-adrenergic agonist",
author = "Persson, {Niklas Daniel {\AA}ke} and Panu Uusalo and Maiken Nedergaard and Lohela, {Terhi J.} and Lilius, {Tuomas O.}",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
doi = "10.1016/j.tips.2022.09.007",
language = "English",
volume = "43",
pages = "1030--1040",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Ltd. * Trends Journals",
number = "12",

}

RIS

TY - JOUR

T1 - Could dexmedetomidine be repurposed as a glymphatic enhancer?

AU - Persson, Niklas Daniel Åke

AU - Uusalo, Panu

AU - Nedergaard, Maiken

AU - Lohela, Terhi J.

AU - Lilius, Tuomas O.

N1 - Publisher Copyright: © 2022 The Authors

PY - 2022

Y1 - 2022

N2 - Cerebrospinal fluid (CSF) flows through the central nervous system (CNS) via the glymphatic pathway to clear the interstitium of metabolic waste. In preclinical studies, glymphatic fluid flow rate increases with low central noradrenergic tone and slow-wave activity during natural sleep and general anesthesia. By contrast, sleep deprivation reduces glymphatic clearance and leads to intracerebral accumulation of metabolic waste, suggesting an underlying mechanism linking sleep disturbances with neurodegenerative diseases. The selective α2-adrenergic agonist dexmedetomidine is a sedative drug that induces slow waves in the electroencephalogram, suppresses central noradrenergic tone, and preserves glymphatic outflow. As recently developed dexmedetomidine formulations enable self-administration, we suggest that dexmedetomidine could serve as a sedative-hypnotic drug to enhance clearance of harmful waste from the brain of those vulnerable to neurodegeneration.

AB - Cerebrospinal fluid (CSF) flows through the central nervous system (CNS) via the glymphatic pathway to clear the interstitium of metabolic waste. In preclinical studies, glymphatic fluid flow rate increases with low central noradrenergic tone and slow-wave activity during natural sleep and general anesthesia. By contrast, sleep deprivation reduces glymphatic clearance and leads to intracerebral accumulation of metabolic waste, suggesting an underlying mechanism linking sleep disturbances with neurodegenerative diseases. The selective α2-adrenergic agonist dexmedetomidine is a sedative drug that induces slow waves in the electroencephalogram, suppresses central noradrenergic tone, and preserves glymphatic outflow. As recently developed dexmedetomidine formulations enable self-administration, we suggest that dexmedetomidine could serve as a sedative-hypnotic drug to enhance clearance of harmful waste from the brain of those vulnerable to neurodegeneration.

KW - cerebrospinal fluid

KW - delirium

KW - dexmedetomidine

KW - glymphatic system

KW - neurodegeneration

KW - α-adrenergic agonist

U2 - 10.1016/j.tips.2022.09.007

DO - 10.1016/j.tips.2022.09.007

M3 - Review

C2 - 36280451

AN - SCOPUS:85140304150

VL - 43

SP - 1030

EP - 1040

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 12

ER -

ID: 345371961